Great interest has been shown in a new class of PPAR agonists being developed for the treatment of NASH (comprising the dual PPAR-α/δ agonist elafibranor [30] and the triple PPAR-α/γ/δ agonist lanifibranor [31]). The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.